Abstract
Bisphosphonates (BPs) are commonly used in the treatment of myeloma-associated osteolytic lesions. Recent reports have suggested that BPs may also exert direct antitumor effects on myeloma cells. Here, we show that the treatment of myeloma cell lines with the combination of the potent BP zoledronate and dexamethasone inhibits cell growth and synergistically induces apoptotic cell death, providing a rationale for potential applications in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mundy GR, Bertoline DR . Bone destruction and hypercalcemia in plasma cell myeloma Semin Oncol 1986 13: 291–299
Bataille R, Chappard D, Basle M . Excessive bone resorption in human plasmacytomas: direct induction by tumor cells in vivo Br J Haematol 1995 90: 721–724
Stashenko P, Dewhirst FE, Peros WJ, Ago JM . Synergistic interactions between interleukin-1, tumor necrosis factor and lymphotoxin in bone resorption J Immunol 1987 138: 1464–1468
Fleisch H . Bisphophonates: pharmacology and use in the treatment of tumor-induced hypercalcemia and metastatic bone disease Drugs 1991 42: 919–944
Coleman RE, Purohit OP . Osteoclast inhibitor for the treatment of bone metatases Cancer Treat Rev 1993 19: 79–103
Rogers MJ, Watts DJ, Russell RG . Overview of bisphosphonates Cancer 1997 80: 1652–1660
Shipman CM, Rogers MJ, Apperley JF, Russel RGG, Croucher PI . Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity Br J Haematol 1997 98: 665–672
Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A . In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates Leukemia 1998 12: 220–229
Dhodapkar MV, Singh J, Metha J, Fassas A, Desikan KR, Perlman M, Munshi NC . Anti-myeloma activity of pamidronate in vivo Br J Haematol 1998 103: 530–532
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Badoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight D . Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events J Clin Oncol 1998 16: 593–602
McCloskey EV, MacLennan ICM, Drayson MT, Chapman C, Dunn J, Kanis JA . A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma Br J Haematol 1998 100: 317–325
Green JR, Muller K, Jaeggi KA . Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound J Bone Miner Res 1994 9: 745–751
Zhang X, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Bairon JM, Bataille R, Klein B . Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma Blood 1994 83: 3654–3663
Carbonari M, Cibati M, Fiorilli M . Measurement of apoptotic cells in peripheral blood Cytometry 1995 22: 161–167
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi CA . A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry J Immunol Meth 1991 139: 271–279
Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F . Features of apoptotic cells measured by flow cytometry Cytometry 1992 13: 795–808
Ogreid D, Ekanger R, Suva RH, Miller JP, Sturm P, Corbin JD, Doskeland SO . Activation of protein kinase isozymes by cyclic nucleotide analogs used singly or in combination. Principles for optimizing the isozyme specificity of analog combinations Eur J Biochem 1985 150: 219–227
Shipman CM, Croucher PI, Russel GR, Helfrich MH, Rogers MJ . The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway Cancer Res 1998 58: 5294–5297
Gibbs JB, Olif A . The potential of farnesyltransferase inhibitors as cancer chemotherapeutics Annu Rev Pharmacol Toxicol 1997 37: 143–166
Dallas SL, Garret IR, Bonewald LF, Gilles J, Boyce BF, Radl J, Mundy GR . Evidence for a vicious cycle between myeloma growth in bone and osteoclastic bone resorption Blood 1994 844: 176a
Barille S, Collette M, Bataille R, Amiot M . Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin Blood 1995 86: 685–691
GR, Raisz LG, Cooper RA, Schechter GP, Salmon S . Evidence for the secretion of an osteoclast stimulating factor in myeloma New Engl J Med 1974 291: 1041–1046
Savage AD, Belson DJ, Vescio RA, Lichtenstein AK, Berenson JR . Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients Blood 1996 88: 105a
Klein B, Zhang XG, Lu ZY, Bataille R . Interleukin-6 in human multiple myeloma Blood 1995 85: 863–872
Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J . Interleukin-6 prevents dexamethasone-induced myeloma cell death Blood 1994 84: 3063–3070
Grigorieva I, Thomas H, Epstein J . The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone Exp Haematol 1998 26: 597–603
Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA . Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J Clin Invest 1991 88: 2095–2105
Acknowledgements
This work was supported in part by: Associazione Italiana per la Ricerca sul Cancro (AIRC); Regione Calabria (POP 94/99); MURST-CNR Biotechnology Program L 95/95; MURST (Cofin 98) and Consiglio Nazionale delle Ricerche (Special Project Biotechnology). We are grateful to Dr B Klein (Molecular Genetics, CNRS, Montpellier Cedex, France) for the generous gift of the XG-1 cell line. We also thank Dr PO Eramo for the expert technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tassone, P., Forciniti, S., Galea, E. et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14, 841–844 (2000). https://doi.org/10.1038/sj.leu.2401770
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401770
Keywords
This article is cited by
-
Bisphosphonates in Multiple Myeloma: Preclinical and Clinical Data
Clinical Reviews in Bone and Mineral Metabolism (2013)
-
Bisphosphonates as antimyeloma drugs
Leukemia (2012)
-
Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
British Journal of Cancer (2011)
-
Targeting Bone as a Therapy for Myeloma
Cancer Microenvironment (2011)
-
Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy
Cancer Chemotherapy and Pharmacology (2010)